CDMO Activity Tracker: Lupin’s CDMO commissions oncology block in India; Cambrex, Axplora, Hovione expand operations

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Nocutil

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

59 API Suppliers, 20 USDMF, 14 CEP/COS, 2 JDMF, 3 EU WC, 10 KDMF, 30 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

329 FDF Dossiers, 53 FDA Orange Book, 228 Europe, 12 Canada, 12 Australia, 8 South Africa, 16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;NASAL - 0.01%, SPRAY, METERED;NASAL - 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 0.004MG/ML, TABLET;ORAL - 0.1MG, TABLET;ORAL - 0.2MG, SPRAY, METERED;NASAL - 0.00083MG/SPRAY, SPRAY, METERED;NASAL - 0.00166MG/SPRAY, SPRAY, METERED;NASAL - 0.15MG/SPRAY, SPRAY, METERED;NASAL - 0.01MG/SPRAY, TABLET;SUBLINGUAL - 0.0277MG, TABLET;SUBLINGUAL - 0.0553MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma, 1 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 3 Kirsch Pharma, 7 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 15 BASF, 1 CD Formulation, 2 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 2 Ingredion Pharma Solutions, 12 Kerry, 10 Microlex e.U, 1 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Prachin Chemical, 7 Roquette, 5 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Sigachi Industries, 1 Silverline Chemicals, 1 Symrise, 2 Ulanqab Kema New Material, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders, 19 Disintegrants & Superdisintegrants, 19 Direct Compression, 17 Solubilizers, 17 Granulation, 13 Lubricants & Glidants, 13 Parenteral, 10 Thickeners and Stabilizers, 9 Chewable & Orodispersible Aids, 7 Emulsifying Agents, 7 Co-Processed Excipients, 7 Controlled & Modified Release, 5 Taste Masking, 5 Topical, 5 Surfactant & Foaming Agents, 3 Coating Systems & Additives, 3 Film Formers & Plasticizers, 2 API Stability Enhancers

DIGITAL CONTENT

31 News #PharmaBuzz

31 News #PharmaBuzz

GLOBAL SALES INFORMATION

18 US Medicaid Prescriptions, 106 Regulatory FDF Prices

MARKET PLACE

9 APIs, 8 FDF Dossiers

PATENTS & EXCLUSIVITIES

12 US Patents, 14 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
29/11/2025	PolyPeptide Group	Switzerland	PolyPeptide Laboratories (Sweden) AB	224MF10122	Desmopressin	2012-07-09	2023-06-28	Ho(¨)gerudsgatan 21, Limhamn
29/11/2025	PolyPeptide Group	Switzerland	PolyPeptide Laboratories (Sweden) AB	306MF10047	Desmopressin	2024-03-27	2024-03-27	Ho(¨)gerudsgatan 21, Limhamn

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Nocutil

Nocutil

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

59 API Suppliers

20 USDMF

14 CEP/COS

2 JDMF

3 EU WC

10 KDMF

30 NDC API

18 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

329 FDF Dossiers

53 FDA Orange Book

228 Europe

12 Canada

12 Australia

8 South Africa

16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;NASAL - 0.01%

SPRAY, METERED;NASAL - 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 0.004MG/ML

TABLET;ORAL - 0.1MG

TABLET;ORAL - 0.2MG

SPRAY, METERED;NASAL - 0.00083MG/SPRAY

SPRAY, METERED;NASAL - 0.00166MG/SPRAY

SPRAY, METERED;NASAL - 0.15MG/SPRAY

SPRAY, METERED;NASAL - 0.01MG/SPRAY

TABLET;SUBLINGUAL - 0.0277MG

TABLET;SUBLINGUAL - 0.0553MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma

1 DKSH

8 Boai NKY Pharmaceuticals Ltd

2 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

3 Kirsch Pharma

7 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

15 BASF

1 CD Formulation

2 DFE Pharma

1 Finar

7 Gangwal Chemicals

2 Ingredion Pharma Solutions

12 Kerry

10 Microlex e.U

1 Nitika Pharmaceutical Specialities

2 Novo Excipients

2 Pharmatrans-Sanaq

4 Pluviaendo

1 Prachin Chemical

7 Roquette

5 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

3 Sigachi Industries

1 Silverline Chemicals

1 Symrise

2 Ulanqab Kema New Material

1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders

19 Disintegrants & Superdisintegrants

19 Direct Compression

17 Solubilizers

17 Granulation

13 Lubricants & Glidants

13 Parenteral

SPRAY, METERED;NASAL - 0.01MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons